CROMSOURCE Continues Strong US Growth With Multiple New Business Awards
Apr 19, 2017, 07:00 ET
VERONA, Italy, April 19, 2017 /CNW/ - CROMSOURCE, an international contract research organization (CRO) providing a comprehensive portfolio of clinical research services to the pharmaceutical, biotechnology, and medical device industries, announced today the recent award of more than €40M in net professional fees - or $42M - for multiple clinical development programs to be delivered in the US. The Company believes this is the direct result of the significant investment in the US that has been made in infrastructure, technology, and most importantly attracting top talent to ensure that CROMSOURCE is considered to be a strong and attractive partner for clients with global clinical outsourcing needs.
(Logo: http://photos.prnewswire.com/prnh/20151005/273774LOGO )
The newly awarded programs are in the areas of Oncology, Rare Disease, and Respiratory - three areas that CROMSOURCE considers to be critical to its future strategy. With the three programs, CROMSOURCE expects to recruit nearly 3,000 patients at approximately 270 investigator sites across the US. This is in addition to an already robust pipeline of opportunities in the US and EU.
"The opportunity to collaborate with blue chip clients in bringing novel life-changing and life-saving medicines to market is what defines our mission and the character of our company. We are excited by these recent awards and are committed as always to delivering results to the highest standards of quality and customer service," stated Dr. Oriana Zerbini, founder and CEO of CROMSOURCE.
Dr. Troy W. McCall, CROMSOURCE Chief Operating Officer, added, "Oriana and I are very pleased that the plan we put in place is resulting in the success that we all knew was achievable - the significant expansion of CROMSOURCE into the world's largest market for clinical outsourcing services. We are very proud of our team for their efforts in demonstrating the value that CROMSOURCE brings to our partners."
In addition to Oncology, Rare Disease, and Respiratory, CROMSOURCE has extensive global experience in Medical Devices, Ophthalmology, and other important areas.
CROMSOURCE is an ISO-certified, international contract research organization providing a comprehensive portfolio of services to the pharmaceutical, biotechnology, and medical device industries. Specializing in clinical development and staffing solutions, we offer a flexible approach to ensure our clients' unique needs are supported. CROMSOURCE is unparalleled in offering an end-to-end guarantee covering trial timelines, enrollment, and price. CROMSOURCE operates offices across all regions of Europe and North America. For more information, visit http://www.cromsource.com.
For further information: April McCall, [email protected], +1-919-896-0280
Share this article